News 2025-05-16
Join Us at Chemspec Europe 2025 in June
As a benchmark exhibition in Europe, Chemspec Europe 2025 focuses on customized chemical solutions and innovative technologies. With its highly specialized positioning, the exhibition has become a core platform for global industry elites to connect resources and expand business networks. The exhibition, which covers the entire industry chain of pharmaceuticals, electronic chemicals, agricultural chemicals and other fields, is not only a hub for technology and knowledge exchange, but also an efficient channel for companies to explore the international market.
Porton Pharma Solutions is a global company with over 4,200 employees and R&D and GMP-compliant manufacturing facilities across the US, EU, and China. It provides customer-centric, innovative, and reliable CDMO solutions for Small Molecules, Tides, Biologics and Conjugates (such as ADCs, AOCs, PDCs, RDCs, etc.), as well as Advanced Therapy Medicinal Products, from pre-clinical to commercial stages. The grand opening of Chemspec Europe 2025 undoubtedly provides an excellent platform for industry enterprises to showcase and exchange ideas. In view of this, Porton will unveil its booth at Booth 4T29 in the Koelnmesse in Germany on June 4-5, 2025, focusing on demonstrating its full-life cycle service capabilities for the research and development and production of small molecule innovative drugs.
- State-of-the-art Technology Platform
- Comprehensive CDMO Solutions
We provide comprehensive pharmaceutical API
development services across all lifecycle stages - from preclinical research to
IND support, and Phase I to Phase III studies, as well as commercial technology
transfer and manufacture.
- Case Studies
Rapid Launch of Innovative Drugs from Preclinical to Commercialization in 18 Months
Porton cordially invites worldwide collaborators to explore emerging opportunities in small molecule drug development through synergistic partnerships. We anticipate engaging with industry peers to discuss transformative trends and leverage cutting-edge technologies to pioneer new paradigms in pharmaceutical innovation. Schedule your exclusive session @ Booth 4T29,our scientists and BD team are eager to meet you in person.
Others
More
News 2025-06-20
Porton Shanghai Pudong R&D and Manufacturing Site Has Passed the EU QP Audit
Porton Pharma Solutions Ltd. (hereinafter “Porton”) is glad to announce that its Shanghai Pudong R&D and Manufacturing Site has passed the EU Qualified Person (QP) audit.

News 2025-06-19
Porton Shanghai Fengxian Manufacturing Site Has Passed the EU QP Audit
The successful completion of the QP audit is a recognition of the quality management system of Shanghai Fengxian Manufacturing Site, demonstrating Porton's commitment to practicing high standard quality management. It marks that Shanghai Fengxian Manufacturing Site can provide CDMO services for small molecules, peptides and oligonucleotides, proteins and conjugate drugs that meet international standards to global customers.